radius health, inc.

We are a biopharmaceutical company dedicatedto transforming the future for underserved, global patient populations in bone health and related areas. We consistently embrace opportunities to improve the lives of our patients, their caregivers, our communities, our partners, and each other.

Amylyx Pharmaceuticals

We have an audacious mission to develop novel therapies for communities with high unmet needs. Where others see challenges, Amylyx sees opportunities that we pursue with urgency, rigorous science, and unwavering commitment. We explore scientific approaches that are tailored to diseases where we can make the greatest difference, agnostic of modality, in order to usher in a new era of advancements. See our community guidelines here: https://www.amylyx.com/social-media-guidelines Please be aware of potential phishing scams imitating Amylyx. All authentic communications from Amylyx will be from the Amylyx.com domain.

Deciphera Pharmaceuticals

As a member of ONO Group, Deciphera is a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer. We are leveraging our proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of innovative medicines. For more information, visit www.deciphera.com.

Ora, Inc.

Ora is the world's leading full-service ophthalmic drug and device development firm with offices in the United States, United Kingdom, Australia, and Asia. For over 45 years, we have proudly helped our clients earn more than 85 product approvals. We support a wide array of organizations, from start-ups to global pharmaceutical and device companies, to efficiently bring their new products from concept to market. Ora's pre-clinical and clinical models, unique methodologies, integrated clinical data solutions, and global regulatory strategies have been refined and proven across thousands of global projects. We bring together the world's most extensive and experienced team of ophthalmic experts, R&D professionals, and management executives to maximize the value of new product initiatives.

Garonit Pharmaceutical

Garonit Pharmaceutical, a US based multi national company is owned by Rohit and Nitin Garg with its headquarters in New Jersey. We take pride in our operations and quality. We remain focused on a world wide platform while maintaining our local feel to the customers. Garonit Pharmaceuticals has successfully served both Fortune 500 companies and small-scale industries across North America, LATAM, and EMEA. Our manufacturing plants in New Jersey, USA, are fully compliant with cGMP and US-FDA regulations. Additionally, we maintain warehouses in Germany and the UK. As one of the few companies in North America, Garonit Pharmaceuticals holds the prestigious CEP from EDQM for CHG20%. Our CHG20% product adheres to the monographs of USP, BP, EP, JP, and IP. In addition to our commercial endeavors, Garonit Pharmaceuticals collaborates with renowned philanthropic organizations such as UNICEF, WHO, and The Red Cross, aiming to create a better world. Through our own trust, the Neelam Garg Foundation, we actively support girls' education initiatives for underprivileged communities.